Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/ijms21113886 http://scihub22266oqcxt.onion/10.3390/ijms21113886 32485958!7312228!32485958     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Mol+Sci 2020 ; 21 (11): ä Nephropedia Template TP {{tp|p=32485958|t=2020. A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity |pdf=|usr=}}{{32485958}} gab.com Text A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity JO: Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32485958 #FOAvip Immunotherapy with chimeric antigen receptor T (CAR-T cells) has been recently approved for patients with relapsed/refractory B-lymphoproliferative neoplasms. Along with great efficacy in patients with poor prognosis, CAR-T cells have been also linked with novel toxicities in a significant portion of patients. Cytokine release syndrome (CRS) and neurotoxicity present with unique clinical phenotypes that have not been previously observed. Nevertheless, they share similar characteristics with endothelial injury syndromes developing post hematopoietic cell transplantation (HCT). Evolution in complement therapeutics has attracted renewed interest in these life-threatening syndromes, primarily concerning transplant-associated thrombotic microangiopathy (TA-TMA). The immune system emerges as a key player not only mediating cytokine responses but potentially contributing to endothelial injury in CAR-T cell toxicity. The interplay between complement, endothelial dysfunction, hypercoagulability, and inflammation seems to be a common denominator in these syndromes. As the indications for CAR-T cells and patient populations expand, there in an unmet clinical need of better understanding of the pathophysiology of CAR-T cell toxicity. Therefore, this review aims to provide state-of-the-art knowledge on cellular therapies in clinical practice (indications and toxicities), endothelial injury syndromes and immunity, as well as potential therapeutic targets. Twit Text FOAVip A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity ????Int J Mol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32485958 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32485958 #FOAvip English Wikipedia <ref>{{Cite pmid|32485958}}</ref> A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity #MMPMID32485958 Gavriilaki E; Sakellari I; Gavriilaki M; Anagnostopoulos A Int J Mol Sci 2020[May]; 21 (11): ä PMID32485958show ga Immunotherapy with chimeric antigen receptor T (CAR-T cells) has been recently approved for patients with relapsed/refractory B-lymphoproliferative neoplasms. Along with great efficacy in patients with poor prognosis, CAR-T cells have been also linked with novel toxicities in a significant portion of patients. Cytokine release syndrome (CRS) and neurotoxicity present with unique clinical phenotypes that have not been previously observed. Nevertheless, they share similar characteristics with endothelial injury syndromes developing post hematopoietic cell transplantation (HCT). Evolution in complement therapeutics has attracted renewed interest in these life-threatening syndromes, primarily concerning transplant-associated thrombotic microangiopathy (TA-TMA). The immune system emerges as a key player not only mediating cytokine responses but potentially contributing to endothelial injury in CAR-T cell toxicity. The interplay between complement, endothelial dysfunction, hypercoagulability, and inflammation seems to be a common denominator in these syndromes. As the indications for CAR-T cells and patient populations expand, there in an unmet clinical need of better understanding of the pathophysiology of CAR-T cell toxicity. Therefore, this review aims to provide state-of-the-art knowledge on cellular therapies in clinical practice (indications and toxicities), endothelial injury syndromes and immunity, as well as potential therapeutic targets. |Animals[MESH] |Complement Inactivating Agents/pharmacology[MESH] |Complement System Proteins/chemistry[MESH] |Cytokine Release Syndrome/immunology/therapy[MESH] |Cytokines/metabolism[MESH] |Hematologic Neoplasms/immunology/*therapy[MESH] |Humans[MESH] |Immunotherapy, Adoptive/*methods[MESH] |Inflammation/drug therapy[MESH] |Mice[MESH] |Phenotype[MESH] |Receptors, Chimeric Antigen/*immunology[MESH] |T-Lymphocytes/immunology[MESH] |Thrombotic Microangiopathies[MESH]A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and(epmc).pdf DeepDyve Pubget Overpricing